Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Arcutis Biotherapeutics Q3 product revenue rises 45% on ZORYVE demand

By Reuters News


Overview

  • US immuno-dermatology firm's Q3 product revenue rose 45% yr/yr, driven by ZORYVE demand growth

  • Q3 net income increased to $8.8 mln from $7.4 mln a year earlier

  • Company raised 2026 full-year net product sales guidance


Outlook

  • Arcutis raises 2026 full-year net product sales guidance to $535 mln–$545 mln

  • Company expects potential FDA approval of ZORYVE cream 0.05% for infants in Q1 2027

  • Arcutis to disclose Phase 2 ZORYVE foam vitiligo trial results and advancement decision by end-2026


Result Drivers

  • DEMAND GROWTH - Co said increased demand for ZORYVE products drove Q3 revenue growth

  • GTN IMPROVEMENTS - Modest improvements in gross-to-net deductions contributed to higher product revenue

  • MARKETING SPEND - Increased marketing, including Skin to Believe In campaign, and sales force expansion supported product growth


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net Income

$8.80 mln

Q3 Operating Expenses

$134.48 mln

Q3 Operating Income

$9.44 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Arcutis Biotherapeutics, Inc. is $38.50, about 20.3% above its November 3 closing price of $32.00

  • The stock recently traded at 30 times the next 12-month earnings vs. a P/E of 40 three months ago


Reuters Recommended Reads

  • Nov 3 - Mirum Pharmaceuticals Q3 net product sales surge, outlook raised

  • Nov 2 - Neurocrine Biosciences Q3 revenue jumps 41% on strong INGREZZA, CRENESSITY, VYKAT XR demand

  • Nov 3 - Amgen Q3 revenue beats expectations on higher volumes


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.